Clinical trials: Vector-Borne Diseases
Febrile Illness, Malaria
Rapid Diagnostic Tests (RDTs) for Malaria in Kampala, Uganda
Malaria remains a disease that causes much death and sickness, especially in sub-Saharan Africa. An accurate, simple, and inexpensive method of diagnosing malaria is urgently needed.
- Trial name
- NCT00327964
- Where
- Uganda
- Volunteers
- 600 people
- Sponsor
- University of California, San Francisco
Plasmodium Falciparum Malaria
Phase I Pediatric FMP2.1/AS02A Trial in Mali
The purpose of this study is to test the safety and dosages of a malaria vaccine in 100 children, 1-6 years old, in Bandiagara, Mali.
- Trial name
- NCT00358332
- Testing
- FMP2.1/AS02A, Rabies vaccine (RabAvert)
- Where
- Mali
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
HIV Infections
Extended Follow-Up of Participants in Preventive HIV Vaccine Studies in Uganda
Two previous studies of an HIV preventive vaccine, the STEP study and the Phambili study, were halted because people who received the vaccine were more likely to become infected with HIV.
- Trial name
- NCT01109342
- Where
- Uganda
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lymphatic Filariasis
Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa
This study will determine if a combination of 3 drugs used to treat the infection that cause lymphatic filariasis (LF) due to Wuchereria bancrofti infection are more effective in killing or sterilizing the adult worms compared to…
- Trial name
- NCT01975441
- Testing
- Diethylcarbamazine, Albendazole, Ivermectin
- Where
- Papua New Guinea
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Malaria
Weekly Dosing of Malarone ® for Prevention of Malaria
The purpose of this study is to determine whether Malarone ®, which is a drug approved to prevent malaria when taken daily, will still effectively prevent malaria if taken weekly.
- Trial name
- MALWEEK (NCT00984256)
- Testing
- Atovaquone Proguanil, Procedure - malaria challenge
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Trypanosomiases, African
ADME Study of Acoziborole in Healthy Subjects
This is a single centre, open-label, single group, non-randomised, single oral dose study in healthy male subjects designed to assess the mass balance recovery, PK, metabolite profile and metabolite identification, and…
- Trial name
- NCT04270981
- Testing
- [14C]-acoziborole capsule, 240 mg containing NMT 9.25 kBq (250 nCi) 14C
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Malaria
Safety, Tolerability & Pharmacokinetics (PK) of Co-administered Single Doses of OZ439 and Mefloquine (MQ) in Healthy Volunteers
OZ439 is a novel, synthetic trioxolane medicine which is related to artemisinin, but has the advantage of a longer elimination half-life so is being developed to be administered together with a potential partner drug e.g.
- Trial name
- NCT01615822
- Testing
- OZ439 100mg, OZ439 400mg, MQ 250 mg, single dose
- Where
- South Africa
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
Preventing Mental Health Problems After Childhood Severe Malaria
This is a randomized trial in which caregivers of children suffering from malaria will be assigned to two treatment conditions to prevent mental health problems in the children.
- Trial name
- NCT03432039
- Testing
- Psychoeducation, Behavioral
- Where
- Uganda
- Volunteers
- 120 people
- Sponsor
- Makerere University
Malaria
A Trial of Intermittent Treatment in the Prevention of Malaria in Senegalese Children
In countries of the Sahel and sub-Sahel, malaria transmission is highly seasonal with nearly all infections occurring during a few months of the year.
- Trial name
- NCT00132561
- Testing
- Sulfadoxine/pyrimethamine and artesunate
- Where
- Senegal
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Yellow Fever Vaccine, Yellow Fever
Yellow Fever Vaccine on Statin/ Non Statin Subjects
Since the 1st pandemic of the 21st century caused by SARS coronavirus, the world has experienced outbreaks of swine origin H1N1 influenza, Ebola and Zika viruses, which have all resulted in global health crises.
- Trial name
- NCT03116802
- Testing
- Stamaril (live attenuated yellow fever vaccine)
- Where
- Singapore
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Singapore General Hospital
Malaria
ACT MALI: Treatment of Malaria Based on Combination Therapies
Test the hypothesis that repeated administration of Artesunate/Amiodaquine, Artesunate/Sulfadoxine-Pyrimethamine and Arthemeter-Lufemantrine for the treatment of consecutive episodes of uncomplicated malaria reduces the incidence…
- Trial name
- NCT00452907
- Testing
- Artesunate, Artesunate + Sulfadoxine-Pyrimethamine, arthemether + lumefantrine
- Where
- Mali
- Volunteers
- 780 people
- Sponsor
- Sanofi
Malaria,Falciparum
A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)
This is a Phase Ib age de-escalation, dose escalation, open-label study to assess the safety and immunogenicity of the multi-stage malaria vaccine candidate R21 plus RH5.1 and/or R78C in Matrix-M in adults aged 18-35 years and…
- Trial name
- VAC093 (NCT06958198)
- Testing
- R21, RH5.1, R78C
- Where
- Burkina Faso
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Spatial Repellents for Malaria Control
The primary objective of the study is to demonstrate and quantify the effectiveness of a spatial repellent (SR) product, in reducing malaria infection in humans under operational program conditions in a humanitarian assistance…
- Trial name
- AEGIS Uganda (NCT06122142)
- Testing
- Transfluthrin - delivery by paid study personnel, Transfluthrin - delivery by voucher system, Transfluthrin - delivery by village health teams
- Where
- 2 sites in Uganda
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Notre Dame
Malaria
Assessment of Safety and Pharmacokinetics of a Low Dose of Methotrexate in Healthy Adult Male Kenyan Volunteers
Previous investigations indicate that methotrexate, an old anticancer drug, could be used at low doses to treat malaria. This is a phase I evaluation to assess the safety and pharmacokinetic profile of this drug in healthy adult…
- Trial name
- NCT00791531
- Testing
- Methotrexate
- Where
- Kenya
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- KEMRI-Wellcome Trust Collaborative Research Program
Malaria, Malaria,Falciparum
Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian Adults
This is a randomized, double-blind, placebo-controlled trial to evaluate safety and tolerability of PfSPZ Vaccine administered as five doses of 9.0x10^5 PfSPZ or normal saline at 0, +2, +4, +6 and +28 days to healthy HIV negative…
- Trial name
- NCT03420053
- Testing
- PfSPZ Vaccine, PfSPZ Challenge
- Where
- Tanzania
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Schistosomiasis, Schistosoma Mansoni
Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults
The study will recruit up to 290 healthy adult males and non-pregnant females into a two-part clinical trial of a vaccine to protect against schistosomiasis caused by infection with S. mansoni.
- Trial name
- NCT03910972
- Testing
- Sm-TSP-2/Alhydrogel® vaccine, Sm-TSP-2/Alhydrogel® vaccine plus AP 10-701, ENGERIX-B Hepatitis B Vaccine
- Where
- Uganda
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Malaria
Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays
Background: Malaria is a disease caused by parasites transmitted to people by mosquitoes. Around the world, there were 241 million cases and 627,000 deaths from malaria in 2020.
- Trial name
- NCT06607003
- Testing
- P. vivax challenge agent derived from PvHMB-CCE001
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Leishmaniasis, Leishmaniasis, Cutaneous
Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis
A clinical trial to asses efficacy and safety of Transition-state Analog Inhibitor of Human Purine Nucleoside Phosphorylase for topical use associated standard antimonial in the treatment of Cutaneous Leishmaniasis in Bahia…
- Conditions
- Leishmaniasis, Leishmaniasis, Cutaneous, Leishmaniasis; American
- Trial name
- NCT03294161
- Testing
- Immucillin DI4G, Meglumine antimoniate
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
Japanese Encephalitis
Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj
A multi-center, open, phase 4 clinical trial to assess the long-term immunogenicity and safety of fourth administration of Boryung Cell-Culture Japanese Encephalitis Vaccine inj.
- Trial name
- BR-JELITE (NCT02532569)
- Testing
- Japanese encephalitis vaccine
- Where
- 9 sites in South Korea
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Plasmodium Falciparum Malaria
Evaluation of Safety and Efficacy of Artemether-Lumefantrine Tablets in African Infants and Children With Uncomplicated P. Falciparum Malaria
This study will assess the safety and efficacy of artemether-lumefantrine tablets (6-dose regimen) in African infants / children with acute uncomplicated falciparum malaria.
- Trial name
- NCT00709969
- Testing
- Artemether-lumefantrine
- Where
- 3 sites in Kenya, Nigeria and 1 more
- Volunteers
- 310 people
- Sponsor
- Novartis